Vaccine against the Corona virus PittCoVacc.

Scientists have created a possible vaccine against the Corona virus, called a PittCoVacc.

Scientists have created a possible vaccine against the Corona virus, which they call "PittCoVacc". According to the study, when testing this vaccine in mice, “PittCoVacc” produced an increase in antibodies against Sars-CoV-2 within two weeks of pricking the fine needle.


Scientists have said that a patch (or patch) the size of a finger (fingerprint) could be a possible vaccine for the deadly corona virus. Scientists found that when tested in mice, it produced Covid-19 antibodies in amounts believed to be sufficient to neutralize the virus. 


The vaccine is described in a research paper published in EBioMedicine, published by The Lancet, and it is believed to be the first to be reviewed by other scientists. The research team at the University of Pittsburgh Medical School said they were able to act quickly, because they laid the groundwork during previous Coronavirus epidemics. "We had previous experience with Sars-CoV in 2003 and Mers-CoV in 2014," said co-author Andrea Gambuto, associate professor of assistive surgery at the university.


These two viruses, which are closely related to Sars-CoV-2, teach us that a specific protein called spike protein, is important for causing immunity to the virus. We knew exactly where to fight this new virus. For this reason it is important to fund vaccine research.


You never know where the next epidemic will come from. " Scientists say that their vaccine filter takes a more established approach, compared to the experimental mRNA vaccine filter, which has entered clinical trials in Seattle.


They called their drug PittCoVacc, the acronym for Pittsburgh Coronavirus, and used laboratory pieces of viral protein to build immunity, in the same way that existing flu vaccines work.


Scientists have also used a new approach to introducing the drug, called the microneedle group, to increase efficacy, which is a patch the size of a fingertip containing 400 small needles, that transports pieces of spike protein across the skin, where the immune response is stronger.


The patch is applied as plaster and then the needles, made entirely of sugar and protein bars, are broken down into the skin. The researchers say their system can be mass-produced, and once manufactured, the vaccine can be placed at room temperature until it is needed, eliminating the need for refrigeration during transportation or storage.


The team plans to apply for approval of the new drugs from the US Food and Drug Administration in anticipation of the start of the first phase of human clinical trials in the next few months.